Last reviewed 2026-04-22 · How we verify

Prednisolone and amoxicillin/clavulanate

Prednisolone and amoxicillin/clavulanate is a Corticosteroid + Beta-lactam antibiotic combination Small molecule drug developed by University of Chicago. It is currently FDA-approved for Inflammatory and infectious conditions requiring concurrent immunosuppression and broad-spectrum antibiotic coverage.

This combination uses prednisolone to suppress immune and inflammatory responses while amoxicillin/clavulanate provides broad-spectrum bacterial coverage with beta-lactamase inhibition.

This combination uses prednisolone to suppress immune and inflammatory responses while amoxicillin/clavulanate provides broad-spectrum bacterial coverage with beta-lactamase inhibition. Used for Inflammatory and infectious conditions requiring concurrent immunosuppression and broad-spectrum antibiotic coverage.

At a glance

Mechanism of action

Prednisolone is a corticosteroid that reduces inflammation and suppresses immune function by inhibiting cytokine production and immune cell activation. Amoxicillin/clavulanate is a beta-lactam antibiotic combination where amoxicillin inhibits bacterial cell wall synthesis and clavulanate protects it from beta-lactamase degradation, extending spectrum to beta-lactamase-producing organisms.

Approved indications

• Inflammatory and infectious conditions requiring concurrent immunosuppression and broad-spectrum antibiotic coverage

Common side effects

• Immunosuppression / increased infection risk
• Gastrointestinal upset (nausea, diarrhea)
• Hyperglycemia
• Insomnia / mood changes
• Allergic reaction (amoxicillin)

Key clinical trials

• Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone (PHASE3)
• Safety and Efficacy of DSM 32444 Postbiotic in the Treatment of Acute Rhinosinusitis (NA)
• Systemic Steroids Plus Antibiotics in Sleep Apnea Syndrome in Children (PHASE4)
• Systemic Methylprednisolone in Chronic Rhinosinusitis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Prednisolone and amoxicillin/clavulanate CI brief — competitive landscape report
• Prednisolone and amoxicillin/clavulanate updates RSS · CI watch RSS
• University of Chicago portfolio CI

Frequently asked questions about Prednisolone and amoxicillin/clavulanate

Related

• Drug class: All Corticosteroid + Beta-lactam antibiotic combination drugs
• Target: All drugs targeting Glucocorticoid receptor (prednisolone); Bacterial peptidoglycan cross-linking (amoxicillin); Beta-lactamase (clavulanate inhibition)
• Manufacturer: University of Chicago — full pipeline
• Therapeutic area: All drugs in Immunology / Infectious Disease
• Indication: Drugs for Inflammatory and infectious conditions requiring concurrent immunosuppression and broad-spectrum antibiotic coverage
• Compare: Prednisolone and amoxicillin/clavulanate vs similar drugs
• Pricing: Prednisolone and amoxicillin/clavulanate cost, discount & access